| Literature DB >> 35915497 |
Odd Bech-Hanssen1,2, Martin Fredholm3,4, Marco Astengo5,3, Sven-Erik Bartfay3,6, Entela Bollano3,6, Göran Dellgren3,7, Kristjan Karason3,6,8, Sven-Erik Ricksten3,4.
Abstract
PURPOSE: Recognition of congestion and hypoperfusion in patients with chronic left ventricular dysfunction (LVD) has therapeutic and prognostic implications. In the present study we hypothesized that a multiparameter echocardiographic grading of right ventricular dysfunction (RVD) can facilitate the characterization of hemodynamic profiles.Entities:
Keywords: Echocardiography; Hemodynamic profile; Left ventricular dysfunction; Right ventricular dysfunction score
Mesh:
Year: 2022 PMID: 35915497 PMCID: PMC9344733 DOI: 10.1186/s12947-022-00290-5
Source DB: PubMed Journal: Cardiovasc Ultrasound ISSN: 1476-7120 Impact factor: 2.263
Variables included in the RVD score and their cut-off values indicating RVD
| Parameter | Cut-off | |
|---|---|---|
| RV afterload | Doppler SPAP (mmHg) | ≥ 40 mmHg |
| RV size | RVEDA/BSA (cm2/m2) | > 12.6 (men), 11.5 (females) |
| RV longitudinal function | TAPSE (mm) | < 17 |
| Tricuspid regurgitation | Multiparameter | ≥ grade 2 |
| RAP | IVC collapsibility (%) | < 50 |
IVC Inferior vena cava, RAP Right atrial pressure by echocardiography, RV Right ventricle, RVD Right ventricular dysfunction, SPAP Systolic pulmonary artery pressure, RV/BSA Right ventricular end diastolic area indexed to body surface area, TAPSE Tricuspid annular plane systolic excursion
Clinical characteristics
| Etiology, % | |
| Dilated cardiomyopathy | 65 |
| Ischemic heart disease | 21 |
| Miscellaneous | 14 |
| Medical treatment, % | |
| Beta-blocker | 94 |
| Loop-diuretic | 70 |
| MCRA | 49 |
| ARB | 37 |
| ACE | 37 |
| ARNi | 26 |
| Anticoagulant | 66 |
| Devices, % | |
| ICD | 43 |
| CRT | 34 |
| Regular pacemaker | 3 |
| Htx work-up, % | |
| Listed for Htx | 48 |
| Not fulfil requirements | 18 |
| Considered ineligible | 19 |
ACE Angiotensin-converting-enzyme inhibitor, ARB Angiotensin receptor II inhibitor, ARNI Angiotensin receptor-neprilysin inhibitor, CRT Cardiac resynchronization therapy, ICD Implantable cardioverter defibrillator, Htx Heart transplantation, MCRA Mineral corticoid receptor antagonist
Clinical, laboratory, functional capacity, echocardiographic and right heart catheterization data on patients with cLVD, dLVD and overt LVF
| Post hoc analysisa | |||||||
|---|---|---|---|---|---|---|---|
| Variable | cLVD ( | dLVD ( | LVF ( | Overall p | cLVD vs dLVD | cLVD vs LVF | dLVD vs LVF |
| Clinical | |||||||
| Age (years) | 53 ± 13 | 54 ± 15 | 55 ± 14 | 0.70 | - | - | - |
| Gender (male, %) | 71 | 83 | 79 | 0.85 | - | - | - |
| Dilated cardiomyopathy (%) | 71 | 44 | 73 | 0.33 | - | - | - |
| Ischemic heart disease (%) | 19 | 48 | 18 | 0.08 | 1.0 | 0.07 | |
| Previous cardiac surgery (%) | 5 | 16 | 9 | 0.35 | - | - | - |
| Rales (%) | 8 | 22 | 45 | 1.0 | 0.54 | ||
| Edema (%) | 21 | 18 | 35 | 0.55 | - | - | - |
| Laboratory | |||||||
| Hemoglobin (g/L) | 140 ± 17 | 130 ± 13 | 137 ± 16 | 1.00 | 0.34 | ||
| Creatinine (mmol/L) | 95 (80; 129) | 92 (84; 140) | 125 (103; 143) | 1.0 | 0.052 | ||
| Bilirubin (µmol/L) | 8.1 (6.0; 10.6) | 12.0 (6.1; 18) | 14 (12; 21.5) | 0.46 | 0.058 | ||
| NT-proBNP (ng/L) | 1120 (571; 2155) | 1980 (1280; 3690) | 5040 (3340; 8395) | 0.09 | |||
| Functional capacity | |||||||
| NYHA group 3–4 (%) | 58 | 88 | 97 | 0.15 | - | - | - |
| Ergo (W) | 90 (76; 120) | 90 (74; 109) | 65 (53; 85) | 1.0 | |||
| Peak VO2 (mL/kg/min) | 14 (12;18) | 14 (11;17) | 12 (9–13) | 0.71 | 0.11 | ||
| LV/LA dimension | |||||||
| LV end-diastolic volume index (ml/m2) | 85 (59; 112) | 105 (92; 130) | 109 (85; 141) | 1.0 | |||
| Left atrial volume index (ml/m2) | 41 (33; 54) | 62 (50; 68) | 62 (51; 83) | 1.0 | |||
| LV function | |||||||
| LV ejection fraction (%) | 32 (25; 40) | 25 (20; 32) | 21 (17; 27) | 0.09 | 0.36 | ||
| LV global longitudinal strain (%) | -8.1 (-10.8; -6.1) | -6.5 (-9.0; -5.1) | -5.5 (-6.6; -2.6) | 0.33 | 0.18 | ||
| Doppler CI (L/min/ m2) | 2.0 (1.8; 2.4) | 1.8 (1.5; 2.1) | 1.6 (1.1; 1.9) | 0.27 | 0.23 | ||
| Proportion with CI < 1.9 L/min/ m2 (%) | 28 | 56 | 76 | 0.11 | 0.48 | ||
| E/E’ | 12.1 (7.7; 17.8) | 16.8 (13; 19.6) | 16.3 (13.5; 21.3) | 0.08 | 0.08 | 1.0 | |
| Increased left atrial pressureb (%) | 37 | 90 | 92 | 1.0 | |||
| Mitral regurgitation ≥ moderate (%) | 21 | 28 | 58 | 1.0 | 0.10 | ||
| Right heart catheterization | |||||||
| Heart rate | 66 ± 11 | 73 ± 10 | 76 ± 12 | 0.71 | 0.16 | ||
| MSAP (mmHg) | 74 ± 14 | 73 ± 10 | 71 ± 8 | 0.96 | - | - | - |
| Pulse pressure (mmHg) | 50 ± 15 | 47 ± 18 | 40 ± 13 | 0.42 | 0.010 | 0.42 | |
| Right atrial pressure (mmHg) | 2 (1; 4) | 5 (3; 8) | 11 (9; 14) | ||||
| Right atrial pressure ≥ 10 mmHg (%) | 2 | 12 | 67 | 0.42 | |||
| SPAP (mmHg) | 26 ± 7 | 42 ± 9 | 49 ± 9 | 0.20 | |||
| MPAP (mmHg) | 15 ± 5 | 28 ± 6 | 34 ± 6 | 0.10 | |||
| PCWP (mmHg) | 6 (4; 10) | 18 (16; 21) | 23 (20; 25) | 0.08 | |||
| Right atrial pressure/PCWP | 0.31 (0.08; 0.50) | 0.29 (0.15; 0.41) | 0.48 (0.34; 0.65) | 1.0 | |||
| Stroke volume index (mL/m2) | 39 ± 8 | 33 ± 8 | 25 ± 7 | 0.053 | |||
| Cardiac index (L/min/m2) | 2.7 ± 0.4 | 2.6 ± 0.8 | 2.1 ± 0.4 | 0.23 | |||
| SaO2 (%) | 95 ± 2 | 95 ± 2 | 94 ± 3 | 0.08 | - | - | - |
| SvO2 (%) | 70 ± 5 | 65 ± 4 | 52 ± 5 | ||||
| PVR (Wood units) | 1.6 (1.2; 1.9) | 1.9 (1.2; 2.4) | 2.4 (1.8; 3.3) | 0.35 | 0.08 | ||
| RV/RA dimension | |||||||
| RVD1 (mm) | 42 ± 8 | 47 ± 10 | 50 ± 6 | 0.13 | 0.23 | ||
| RVEDA/BSA (cm2/m2) | 9.8 ± 2.5 | 11.4 ± 4.0 | 12.3 ± 2.8 | 0.28 | 0.23 | ||
| RAAI (cm2/m2) | 10.0 ± 3.5 | 12.3 ± 5.8 | 13.9 ± 3.6 | 0.20 | 0.07 | ||
| RV function | |||||||
| 5-point RVD score | 1 (0; 1) | 1(1; 3) | 3.0 (2; 4) | ||||
| IVC collapsibility (%) | 79 (55; 100) | 64 (40; 78) | 26 (17; 39) | 0.21 | |||
| S’ velocity (cm/s) | 9 (8; 11) | 8 (7; 10) | 8 (6; 9) | 0.12 | - | - | |
| Tricuspid regurgitation ≥ moderate (%) | 7 | 16 | 45 | 1.0 | |||
Bold represents significant p value
Values are mean ± standard deviation, median (IQR 25%;75%), or numbers and percent as appropriate. A p-value < 0.05 was considered significant
BSA Body surface area, cLVD Compensated left ventricular dysfunction, dLVD decompensated left ventricular dysfunction, E/E’ ratio between early diastolic blood pool and annular velocity, Ergo Ergospirometry work load, GLV Global left ventricular strain, LVEDVI Left ventricular end-diastolic volume indexed to body surface area, LV Left ventricle, LVEF Left ventricular ejection fraction, LVF Left ventricular failure, MR Mitral regurgitation, MSAP Mean systemic arterial pressure, MPAP Mean pulmonary artery pressure, NYHA New York Heart Association class, PA Pulmonary artery, PCWP Pulmonary capillary wedge pressure, PVR Pulmonary vascular resistance, RAAI Right atrial area index, RV Right ventricular area in diastole, RVD1 Right ventricular inflow diameter, RVD Right ventricular dysfunction, S’ peak systolic tissue velocity, SvO mixed venous oxygen saturation, VO maximal oxygen consumption
aPost-hoc analysis significance values have been adjusted by the Bonferroni correction for multiple tests
bIncreased left atrial pressure using the proposed algorithm by the American Society of Echocardiography
Fig. 1Box-plots showing the relationship between compensated left ventricular dysfunction (cLVD), decompensated left ventricular dysfunction (dLVD), overt left ventricular failure (LVF) and (A) the right ventricular end-diastolic pressure (RVEDP), (B) pulmonary artery elastance (Ea), (C) the ratio between right ventricular and pulmonary artery elastances (Ees/Ea), (D) the proximal diameter of the right ventricular outflow tract (RVOTProx), (E) the ratio between the right ventricular diastolic area and the length (RVEDA/RVD3), (F) tricuspid annular plane systolic excursion (TAPSE), (G) right ventricular free-wall strain (RVStr), (H) fractional area change and (I) the right ventricular dysfunction (RVD) score. Significance values have been adjusted by the Bonferroni correction for multiple tests
Fig. 2Crosstabs that shows the agreement between (A) increased pulmonary capillary wedge pressure (PCWP) at right heart catheterization and left atrial pressure (LAP) by echocardiography and (B) reduced SvO2 and Doppler cardiac index (CI)
Diagnostic performance of cut-off values to detect patients with decompensation and overt LVF
| Cut-off | Sensitivity (95% CI) | Specificity (95% CI) | PLR (95% CI) | NLR (95% CI) | |
|---|---|---|---|---|---|
| Decompensated LVD (PCWP ≥ 15 mmHg) | |||||
| NT-proBNP | ≥ 2000 ng/L | 75 (60–83) | 73 (58–84) | 2.7 (1.7–4.8) | 0.37 (0.23–0.59) |
| LVEF | < 27% | 69 (56–79) | 69 (54–81) | 2.2 (1.4–3.6) | 0.45 (0.29–0.69) |
| Standard echocardiography | 91(80–97) | 68 (49–82) | 2.8 (1.7–4.9) | 0.13 (0.05–0.33) | |
| RVD score | ≥ 1 | 96 (88–99) | 41 (26–58) | 1.6 (1.2–2.2) | 0.09 (0.02–0.37) |
| RVD score | ≥ 2 | 76 (64–86) | 85 (70–94) | 5.2 (2.3–11.8) | 0.28 (0.17–0.46) |
| Overt LVF (PCWP ≥ 15 mmHg and SvO2 < 60%) | |||||
| NT-proBNP | ≥ 3100 ng/L | 82 (66–91) | 77 (65–85) | 3.5 (2.2–5.6) | 0.24 (0.11–0.50) |
| LVEF | < 25% | 61 (44–75) | 69 (57–78) | 1.9 (1.2–3.0) | 0.57 (0.37–0.90) |
| Standard echocardiography | 73 (54–86) | 74 (60–85) | 2.9 (1.7–4.9) | 0.36 (0.19–0.70) | |
| RVD score | ≥ 2 | 97 (84–99) | 72 (59–82) | 3.5 (2.3–5.3) | 0.04 (0.006–0.30) |
| RVD score | ≥ 4 | 47 (31–64) | 93 (83–97) | 6.7 (2.4–18.4) | 0.57 (0.41–0.80) |
CI Confidence interval, LVD Left ventricular dysfunction, LVF Left ventricular failure, NLR Negative likelihood ratio, PCWP Pulmonary capillary wedge pressure, PLR Positive likelihood ratio, RVF Right ventricular failure, RVD Right ventricular dysfunction, SvO mixed venous saturation
Fig. 3Receiver operator characteristic curves for detection of (A) decompensation and (B) overt left ventricular failure comparing the RVD score with NTproBNP, global longitudinal strain (GLVStr), left ventricular ejection fraction (LVEF), ratio between early diastolic mitral flow velocity and the tissue Doppler velocity (E/E’). (C) Diagnostic algorithm for assessment of hemodynamic profile in patients with chronic left ventricular dysfunction (LVD)
Fig. 4The dynamic nature of RVD illustrated by a patient with ischemic cardiomyopathy. At baseline (upper panel) the patient had biventricular failure with at catheterization PCWP 30 mmHg, RVEDP 17 mmHg, SvO2 45% and NT-proBNP 5000 ng/L. The RVD score was 5 with moderate pulmonary hypertension, reduced TAPSE, RV dilatation, increased central venous pressure and severe tricuspid regurgitation. One week later (middle panel) after treatment with levosimendan and intravenous furosemide, NT-proBNP was 1080 ng/L and the RVD score was 1 due to reduced TAPSE. Six weeks later (lower panel), the patient was in NYHA class IIIb, NT-proBNP was 2370 and the RVD score 3. The hemodynamic profile from the RVD score indicated at baseline that the patient was wet-cold, one week later dry-warm or wet-warm and after 6 weeks wet-cold or wet-warm